Karin Berthine Fieten

Karin Berthine Fieten

Auto-generated profile, based on publicly available information

Karin Berthine Fieten

SIAF / Dutch Asthma Center Davos, Davos, Switzerland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2018 in International Archives of Allergy and Immunology
Verified
Journal Article
Open access
PDF file
KFKarin B. Fieten
Karin B. Fieten
JTJoan E.E. Totté
Joan E.E. Totté
ELEvgeni Levin
Evgeni Levin
MRMarta Reyman
Marta Reyman
YMYolanda Meijer
Yolanda Meijer
SPSuzanne G.M.A. Pasmans
Suzanne G.M.A. Pasmans
Background: Exposure to microbes may be important in the development of atopic disease. Atopic diseases have been associated with specific characteristics of the intestinal microbiome. The link between intestinal microbiota and food allergy has rarely been studied, and the gold standard for diagnosing food allergy (double-blind placebo-controlled food challenge [DBPCFC]) has seldom been used. We aimed to distinguish fecal microbial signatures for food allergy in children with atopic dermatitis (AD). Methods: Pediatric patients with AD, with and without food allergy, were included in this cross-sectional observational pilot study. AD was diagnosed according to the UK Working Party criteria. Food allergy was defined as a positive DBPCFC or a convincing clinical history, in combination with sensitization to the relevant food allergen. Fecal samples were analyzed using 16S rRNA microbial analysis. Microbial signature species, discriminating between the presence and absence food allergy, were selected by elastic net regression. Results: Eighty-two children with AD (39 girls) with a median age of 2.5 years, and 20 of whom were diagnosed with food allergy, provided fecal samples. Food allergy to peanut and cow's milk was the most common. Six bacterial species from the fecal microbiome were identified, that, when combined, distinguished between children with and without food allergy: Bifidobacterium breve, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Escherichia coli, Faecalibacterium prausnitzii, and Akkermansia muciniphila (AUC 0.83, sensitivity 0.77, specificity 0.80). Conclusions: In this pilot study, we identified a microbial signature in children with AD that discriminates between the absence and presence of food allergy. Future studies are needed to confirm our findings.

15 February 2022 in Allergy
Verified
Journal Article
Open access
PDF file
KFKarin B. Fieten
Karin B. Fieten
MDMarieke T. Drijver‐Messelink
Marieke T. Drijver‐Messelink
ACAnnalisa Cogo
Annalisa Cogo
DCDenis Charpin
Denis Charpin
MSMilena Sokolowska
Milena Sokolowska
CACezmi A. Akdis
Cezmi A. Akdis
Currently available European Alpine Altitude Climate Treatment (AACT) programs combine the physical characteristics of altitude with the avoidance of environmental triggers in the alpine climate and a personalized multidisciplinary pulmonary rehabilitation approach. The reduced barometric pressure, oxygen pressure, and air density, the relatively low temperature and humidity, and the increased UV radiation at moderate altitude induce several physiological and immunological adaptation responses. The environmental characteristics of the alpine climate include reduced aeroallergens such as house dust mites (HDM), pollen, fungi, and less air pollution. These combined factors seem to have immunomodulatory effects controlling pathogenic inflammatory responses and favoring less neuro‐immune stress in patients with different asthma phenotypes. The extensive multidisciplinary treatment program may further contribute to the observed clinical improvement by AACT in asthma control and quality of life, fewer exacerbations and hospitalizations, reduced need for oral corticosteroids (OCS), improved lung function, decreased airway hyperresponsiveness (AHR), improved exercise tolerance, and improved sinonasal outcomes. Based on observational studies and expert opinion, AACT represents a valuable therapy for those patients irrespective of their asthma phenotype, who cannot achieve optimal control of their complex condition despite all the advances in medical science and treatment according to guidelines, and therefore run the risk of falling into a downward spiral of loss of physical and mental health. In the light of the observed rapid decrease in inflammation and immunomodulatory effects, AACT can be considered as a natural treatment that targets biological pathways.

9 February 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JTJ.E.E. Totté
J.E.E. Totté
LPLuba Pardo
Luba Pardo
KFK.B. Fieten
K.B. Fieten
MVM.C. Vos
M.C. Vos
TBT.J. van Den Broek
T.J. van Den Broek
SPS.G.M.A. Pasmans
S.G.M.A. Pasmans

11 September 2019 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
MMMinke M.F. van Mierlo
Minke M.F. van Mierlo
JTJoan E.E. Totté
Joan E.E. Totté
KFKarin B. Fieten
Karin B. Fieten
TBTim J. van Den Broek
Tim J. van Den Broek
FSFrank H.J. Schuren
Frank H.J. Schuren
SPSuzanne G.M.A. Pasmans
Suzanne G.M.A. Pasmans

14 November 2018 in Allergy
Verified
Journal Article
Open access
PDF file
KFKarin B. Fieten
Karin B. Fieten
LRLucia H. Rijssenbeek‐Nouwens
Lucia H. Rijssenbeek‐Nouwens
SHSimone Hashimoto
Simone Hashimoto
EBElisabeth H. Bel
Elisabeth H. Bel
EWEls J. Weersink
Els J. Weersink

15 December 2017 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
KFK. B. Fieten
K. B. Fieten
RSR. Schappin
R. Schappin
WZW. T. Zijlstra
W. T. Zijlstra
LFL. Figee
L. Figee
JBJ. Beutler
J. Beutler
SPS. G. M. A. Pasmans
S. G. M. A. Pasmans